What is the main purpose of the amendment to the credit agreement?

The main purposes of the amendment are to replace the LIBOR benchmark with Term SOFR for USD-denominated loans, and to extend the maturity date of the revolving credit facility by one year for consenting lenders. It also adjusts the look-back period for calculating certain covenant exclusions.

How does the change from LIBOR to Term SOFR affect the company?

This change aligns the company's credit agreement with the broader financial market's transition away from LIBOR. Term SOFR is intended to be a more robust and reliable benchmark rate. The specific impact on borrowing costs will depend on the applicable credit spread adjustments and the future movement of SOFR.

What is the significance of extending the credit facility's maturity date?

Extending the maturity date from May 2026 to May 2027 provides Boston Scientific with greater financial flexibility and a longer runway for its credit facilities. This can be beneficial for long-term strategic planning and reduces immediate refinancing risk.

How does the reset of the look-back period for EBITDA exclusions impact financial covenants?

By resetting the look-back period to December 31, 2022, the company can now exclude more recent litigation payments and restructuring charges when calculating its Maximum Leverage Ratio. This may provide more headroom under the covenant, as recent large expenses incurred after the previous March 31, 2021, cut-off can be considered for exclusion.

BSX 8-K SEC Disclosure

Summary

Boston Scientific Corporation (BSX) has filed an 8-K report detailing a second amendment to its $2.750 billion revolving credit agreement. The primary focus of this amendment is to transition from LIBOR to Term SOFR for its USD-denominated Eurocurrency Rate, aligning with broader market shifts. Additionally, the amendment extends the maturity date of the credit facility for consenting lenders by one year, from May 10, 2026, to May 10, 2027. This extension provides the company with a longer-term financing runway and enhances financial flexibility. Another significant change involves the reset of the look-back period for certain exclusions from Consolidated EBITDA calculations when determining the Maximum Leverage Ratio covenant. This period has been moved from March 31, 2021, to December 31, 2022. This adjustment allows for a more current assessment of the company's leverage, potentially providing more room under the covenant by considering more recent charges related to litigation and restructuring initiatives. The specific exclusion limits for these items remain substantial, with up to $1 billion for Cash Litigation Payments and $500 million for restructuring charges since the new look-back date.

Key Highlights

1Amendment to a $2.750 billion revolving credit agreement filed on March 1, 2023.
2Transition from LIBOR to Term SOFR for the Eurocurrency Rate for Dollars.
3Extension of the credit facility's maturity date for consenting lenders from May 10, 2026, to May 10, 2027.
4Reset of the look-back period for excluding Cash Litigation Payments and restructuring charges from Consolidated EBITDA to December 31, 2022.
5Increased exclusion limit for Cash Litigation Payments to $1 billion plus accrued legal liabilities since December 31, 2022.
6Maintained exclusion limit for restructuring and related charges at $500 million since December 31, 2022.
7The amendment aims to enhance financial flexibility and align credit agreements with prevailing market benchmarks.

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Mar 1, 2023)

Summary

Key Highlights

Frequently Asked Questions